This post was originally published on this site
This healthcare pioneer’s roots date all the back to the late 19th century. NVS has stayed in business for good reason. The company’s drugs and therapies have legitimate merit. Perhaps most important is the fact that NVS’s drug researchers continue to push the envelope with breakthrough innovations.
Is NVS a Buy after its slow first half to 2021? Is the stock destined to move sideways or even decline in the months ahead? I answer those questions below.
